Reading size

PACK IN HAND · ONE-PAGE CHECK

Medicine pack check sheet

Print this sheet or fill it in before speaking with a pharmacist or clinician. Copy only what is printed on the pack in hand. The published fields below are starting points from this record, not proof that your pack is the same product.

Published record starting point

Record display name
TRINTELLIX
Generic name / active ingredient
vortioxetine
Dosage-form class
Dosage form and presentation as documented in the linked primary label
Route
Oral
Record reviewed
2026-08-30

Copy from the pack in hand

Source-linked reading points

  • U.S. 5, 10 and 20 mg are labelled vortioxetine amounts per tablet, not tablets per dose or doses per day. The EU also lists a 15 mg tablet and 20 mg/mL oral drops. Mg per tablet and mg per mL are different units and must not be self-converted or substituted by colour.
  • Do not confuse TRINTELLIX/BRINTELLIX with BRILINTA. BRILINTA contains ticagrelor and is an antiplatelet medicine. If a list, prescription or pack name is unclear, stop guessing from the name and have a pharmacist or prescriber check the actual packaging.
  • MAOIs, linezolid, intravenous methylene blue and other serotonergic antidepressants, tramadol, lithium, buspirone, amphetamines, tryptophan or St John's wort are priority serotonin-syndrome checks. Fever with agitation, tremor, muscle rigidity, diarrhoea, altered awareness or seizures requires immediate local emergency support.
  • Aspirin, NSAID pain medicines, warfarin, antiplatelets or other anticoagulants may add bleeding risk. Older adults, people taking diuretics or those who are volume depleted also need priority review for hyponatraemia. New severe bleeding, marked weakness, headache, confusion, unsteady gait, falls, seizures or altered awareness needs timely medical assessment.

Reviewed presentation examples — compare every field

  • Vortioxetine 5 mg per tablet; 30-tablet bottleNDC 64764-720-30
  • Vortioxetine 10 mg per tablet; 30-tablet bottleNDC 64764-730-30
  • Vortioxetine 20 mg per tablet; 30-tablet bottleNDC 64764-750-30

EDITORIAL RECORD

Who prepared and checked this page

Byline
OriginDrug Content Editorial
Review role
Public primary-source verification
Last reviewed
2026-08-30
Source record
7 clickable primary-source entry points are listed with this dossier.

The review role checks source traceability, stated market, document version and product-identity fields. It is not a claim of clinical licensure, prescribing authority or individual pharmacy service. Read the editorial policy.

Search records
Enlarged public-label image